HealthDay News — In a clinical practice guideline issued by the American Society for Radiation Oncology and published online Feb. 27 in Practical Radiation Oncology, evidence-based recommendations are ...

Dr. Sara M. Tolaney discussed HER2-positive breast cancer, highlighting key trials, evolving treatment strategies, and the ...

The FDA granted orphan drug designation to HLX22 for gastric cancer, advancing global phase 3 trials to improve first-line ...

The conversion from accelerated approval to traditional approval was supported by data from the phase 3 KEYNOTE-811 trial.

Sorafenib as a single agent, although well tolerated, does not exhibit significant activity in the treatment of metastatic breast cancer (MBC). Sorafenib, in combination with capecitabine ...

Sales of PBYI's sole-marketed drug, Nerlynx, exceeded management's expectations in fourth-quarter 2024. Also, ongoing studies on alisertib are progressing well.

Experts discuss treatment options for HER2-positive metastatic breast cancer following progression on trastuzumab deruxtecan (T-DXd), weighing real-world data on tucatinib-capecitabine-trastuzumab ...

For most patients, definitive treatment with combined modality therapy is recommended using concurrent 5-fluorouracil or capecitabine ... role in managing anal cancer, offering patients an ...

Daiichi Sankyo launches Datroway in Japan for patients with previously treated unresectable or recurrent HR positive, HER2 negative breast cancer: Tokyo Thursday, March 20, 2025, ...

The ADC is stable in the bloodstream and internalised by cancer cells, where the payload ... plus Roche's chemotherapeutic drug Xeloda (capecitabine), or Roche's HER2 therapy Herceptin ...